Beam Therapeutics is set to present updated data from its BEACON Phase 1/2 clinical trial of BEAM-101, an investigational base-editing therapy for sickle cell disease (SCD), at the 2025 Tandem Meetings in Honolulu, Hawaii. The presentation will feature data from patients treated with BEAM-101, building upon initial results presented at the 66th American Society of Hematology (ASH) Annual Meeting in December 2024.
BEAM-101: A Novel Approach to SCD Treatment
BEAM-101 is a genetically modified cell therapy designed to address the root cause of SCD by increasing fetal hemoglobin (HbF) production. The therapy involves base editing autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) to inhibit BCL11A, a transcriptional repressor, in the promoter regions of the HBG1/2 genes. This edit aims to mimic the effects of hereditary persistence of fetal hemoglobin, increasing HbF levels and reducing sickle hemoglobin (HbS).
The BEACON trial is an open-label, single-arm, multicenter study evaluating the safety and efficacy of BEAM-101 in adult patients with severe SCD and vaso-occlusive crises (VOCs). Initial data from seven patients showed promising results, including robust and durable increases in HbF, reductions in HbS, rapid neutrophil and platelet engraftment, and normalized or improved markers of hemolysis. The safety profile of BEAM-101 was consistent with busulfan conditioning and autologous hematopoietic stem cell transplantation.
ESCAPE Platform for Non-Genotoxic Conditioning
Beam Therapeutics is also developing its Engineered Stem Cell Antibody Evasion (ESCAPE) platform as a wave 2 approach to SCD treatment. ESCAPE aims to provide the same ex vivo-manufactured cell product as BEAM-101 but with a non-genotoxic alternative to traditional chemotherapy conditioning. Preclinical data in non-human primates demonstrated engraftment of base-edited cells using antibody conditioning. A Phase 1 healthy volunteer clinical trial of BEAM-103, an anti-CD117 monoclonal antibody designed to suppress hematopoietic stem and progenitor cells, is expected to initiate by the end of 2025.
Broader Pipeline and Financial Outlook
Beyond SCD, Beam Therapeutics is advancing its genetic disease franchise with programs like BEAM-302 for alpha-1 antitrypsin deficiency (AATD) and BEAM-301 for glycogen storage disease type 1a (GSD1a). Initial data from the Phase 1/2 trial of BEAM-302 is expected in the first half of 2025, and dosing in the Phase 1/2 trial of BEAM-301 is anticipated to commence in early 2025.
As of December 31, 2024, Beam Therapeutics estimates having $850.7 million in cash, cash equivalents, and marketable securities, which is expected to fund operating plans into 2027, including commercial readiness activities for BEAM-101. Beam expects to dose 30 patients in the BEACON trial by mid-2025 and present updated data.
